Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab
Mia Bendix,Anders Dige,Søren Peter Jørgensen,Jens Frederik Dahlerup,Bo Martin Bibby,Bent Deleuran,Bent Deleuran,Jørgen Agnholt +7 more
TL;DR: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression in mucosa within treatment groups, and this did not induce a statistically significant decreased disease activity.
read more
Abstract: Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6. Results: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab. Conclusions: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Role of Vitamin D in Celiac Disease and Inflammatory Bowel Diseases
Claudia Infantino,Roberta Francavilla,Adriana Vella,S. Cenni,Nicola Principi,Caterina Strisciuglio,Susanna Esposito +6 more
TL;DR: In this paper , the authors evaluated the relationship between VD, CD, and IBD and found that VD may exert many extra-skeletal functions, mainly through a relevant modulation of the innate and adaptive immune system.
Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up
Mia Bendix,Anders Dige,Søren Peter Jørgensen,Jens Frederik Dahlerup,Bo Martin Bibby,Bent Deleuran,Jørgen Agnholt +6 more
TL;DR: In a follow-up study, this paper investigated whether seven-week vitamin D treatment affected the infliximab response in the following 45 weeks compared to placebo, and the results showed that group D- patients had greater need for inflixinimab dose escalation during followup compared to group D+ (p = 0.05) and Group D+ had lower median calprotectin levels week 15 and week 23.
17
Vitamin D for the treatment of inflammatory bowel disease
Chris Wallace,Morris Gordon,Vassiliki Sinopoulou,Berkeley N. Limketkai +3 more
TL;DR: The available evidence suggests that vitamin D may have a beneficial effect on clinical relapse in IBD, but the certainty of the evidence is very low. There is a lack of high-quality studies and inconsistent results across studies. Further research is needed to confirm the benefits and harms of vitamin D for the treatment of IBD.
11
The use of vitamin D for patients with inflammatory bowel diseases.
Júlia Novaes Matias,Vinícius Marinho Lima,Giovanna Soares Nutels,LUCAS FORNARI LAURINDO,Sandra Maria Barbalho,Ricardo de Alvares Goulart,Adriano Cressoni Araújo,Rodrigo Buzinaro Suzuki,Elen Landgraf Guiguer +8 more
TL;DR: There is still a need for standardized studies to establish how the supplementation of VD should be performed and the doses to be administered, as available clinical trials do not have standardization of doses and routes of administration.
8
Evaluation of periodontal status and cytokine levels in saliva and gingival crevicular fluid of patients with inflammatory bowel diseases
TL;DR: In this paper , the salivary and gingival crevicular fluid (GCF) concentrations of cytokines were analyzed using ELISA, and the interrelationships among these cytokines, IBD conditions, and periodontal diseases were analyzed.
References
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber,Bruce E. Sands,Steve Lewitzky,Marc Vandemeulebroecke,Walter Reinisch,Peter D.R. Higgins,Jan Wehkamp,Brian G. Feagan,Michael D Yao,Marek Karczewski,Jacek Karczewski,Nicole Pezous,Stephan Bek,Gerard Bruin,Bjoern Mellgard,Claudia Berger,Marco Londei,Arthur P. Bertolino,Gervais Tougas,Simon Travis +19 more
TL;DR: Blockade of IL-17A was ineffective and higher rates of adverse events were noted compared with placebo, and unfavourable responses on secukinumab were driven by patients with elevated inflammatory markers.
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis
Ken Sugimoto,Atsuhiro Ogawa,Atsuhiro Ogawa,Emiko Mizoguchi,Yasuyo Shimomura,Akira Andoh,Atul K. Bhan,Richard S. Blumberg,Ramnik J. Xavier,Atsushi Mizoguchi +9 more
TL;DR: A novel microinjection-based local gene-delivery system that is capable of targeting the inflamed intestine and demonstrating a therapeutic potency for IL-22-mediated activation of the innate immune pathway in a mouse model of Th2-mediated colitis that induces disease with characteristics similar to that of IBD ulcerative colitis is developed.
Immunomodulatory effects of Vitamin D in multiple sclerosis
TL;DR: Levels of 1,25(OH)(2)D(3) plays an important role in T cell homeostasis during the course of multiple sclerosis, thus making correction of its deficiency may be useful during treatment of the disease.
1,25-Dihydroxyvitamin D 3 ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A
Sneha Joshi,Luiz C. Pantalena,Xikui Liu,Sarah L. Gaffen,Sarah L. Gaffen,Hong Liu,Christine Rohowsky-Kochan,Kenji Ichiyama,Akihiko Yoshimura,Lawrence Steinman,Sylvia Christakos,Sawsan Youssef +11 more
TL;DR: In vivo treatment of mice with ongoing experimental autoimmune encephalomyelitis diminishes paralysis and progression of the disease and reduces IL-17A-secreting T cells in the periphery and central nervous system (CNS).
463
Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective.
Casey T. Weaver,Robin D. Hatton +1 more
TL;DR: It is speculated that the co-evolution of these adaptive immune pathways might have given primitive vertebrates a means to benefit from the diversification of their commensal microbiota.
421
Related Papers (5)
Geert R. D'Haens,Severine Vermeire,Guy Lambrecht,Filip Baert,Peter Bossuyt,Benjamin Pariente,Anthony Buisson,Yoram Bouhnik,Jérôme Filippi,Janneke van der Woude,Philippe Van Hootegem,Jacques Moreau,Edouard Louis,Denis Franchimont,Martine De Vos,Fazia Mana,Laurent Peyrin-Biroulet,Hedia Brixi,Matthieu Allez,Philip Caenepeel,Alexandre Aubourg,Bas Oldenburg,Marieke Pierik,Ann Gils,Sylvie Chevret,David Laharie,Patricia Détré,Marie Jo Bertin,Sabrina Williams +28 more